Abstract
The death ligand TRAIL has been suggested as a suitable biological agent for the selective induction of cell death in cancer cells. Moreover, TRAIL synergizes with DNA-damaging therapies such as chemotherapeutic drugs or ionizing irradiation (IR). Here, we show that synergy of TRAIL and IR, that is, crosssensitization between TRAIL and IR for induction of apoptosis, entirely depends on Bax proficiency in human DU145 and HCT116 carcinoma cells. DU145 prostate carcinoma cells that have lost Bax protein expression due to mutation fail to activate caspase-3 and -9 when exposed to TRAIL and IR. In contrast, TRAIL sensitized for IR-induced apoptosis and vice versa upon reconstitution of Bax expression. Notably, both DU145 and HCT116 still express significant levels of the multidomain proapoptotic Bcl-2 homolog Bak. This indicates that Bak is not sufficient to mediate crosssensitization and synergism between IR and TRAIL. These data clearly establish distinct roles for Bax and Bak in linking the TRAIL death receptor pathway to the mitochondrial apoptosis signaling cascade upon DNA damage by IR.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH . (1999). J. Clin. Invest., 104, 155–162.
Ballestrero A, Nencioni A, Boy D, Rocco I, Garuti A, Mela GS, Van Parijs L, Brossart P, Wesselborg S and Patrone F . (2004). Clin. Cancer Res., 10, 1463–1470.
Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-Wienhues A, Faltin H, Bamberg M, Budach W and Schulze-Osthoff K . (2000). Oncogene, 19, 1181–1190.
Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M, Schulze-Osthoff K and Budach W . (2001). Oncogene, 20, 2190–2196.
Bonavida B, Ng CP, Jazirehi A, Schiller G and Mizutani Y . (1999). Int. J. Oncol., 15, 793–802.
Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B and Daniel PT . (2002). Leukemia, 16, 1035–1044.
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B . (1999). J. Clin. Invest., 104, 263–269.
Cartron P-F, Juin P, Oliver L, Martin S, Meflah K and Vallette FM . (2003). Mol. Cell. Biol., 23, 4701–4712.
Cheng EH, Sheiko TV, Fisher JK, Craigen WJ and Korsmeyer SJ . (2003). Science, 301, 513–517.
Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T and Korsmeyer SJ . (2001). Mol. Cell, 8, 705–711.
Coney LR, Daniel PT, Sanborn D, Dhein J, Debatin KM, Krammer PH and Zurawski Jr VR . (1994). Int. J. Cancer, 58, 562–567.
Daniel PT, Schulze-Osthoff K, Belka C and Güner D . (2003). Essays Biochem., 39, 73–88.
Daniel PT, Sturm I, Wieder T and Schulze-Osthoff K . (2001). Leukemia, 15, 1022–1032.
Deng Y, Lin Y and Wu X . (2002). Genes Dev., 16, 33–45.
Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P and Krammer PH . (1992). J. Immunol., 149, 3166–3173.
Eberle J, Fecker LF, Hossini AM, Wieder T, Daniel PT, Orfanos CE and Geilen CC . (2003). Oncogene, 22, 9131–9141.
Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Janicke RU, Porter AG, Belka C, Gregor M, Schulze-Osthoff K and Wesselborg S . (2000). Oncogene, 19, 4563–4573.
Eskes R, Desagher S, Antonsson B and Martinou JC . (2000). Mol. Cell. Biol., 20, 929–935.
Essmann F, Wieder T, Otto A, Muller EC, Dörken B and Daniel PT . (2000). Biochem. J., 346, 777–783.
Friedrich K, Wieder T, von Haefen C, Radetzki S, Jänicke R, Schulze-Osthoff K, Dörken B and Daniel PT . (2001). Oncogene, 20, 2749–2760.
Fulda S, Meyer E and Debatin KM . (2002). Oncogene, 21, 2283–2294.
Gillissen B, Essmann F, Graupner V, Stärck L, Radetzki S, Dörken B, Schulze-Osthoff K and Daniel PT . (2003). EMBO J., 22, 3580–3590.
Gliniak B and Le T . (1999). Cancer Res., 59, 6153–6158.
Güner D, Sturm I, Hemmati PG, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M and Daniel PT . (2002). Int. J. Cancer, 103, 445–454.
Hasenjäger A, Gillissen B, Müller A, Normand G, Hemmati PG, Schuler M, Dörken B and Daniel PT . (2004). Oncogene, 23, 4523–4535.
Hemmati PG, Gillissen B, von Haefen C, Wendt J, Stärck L, Güner D, Dörken B and Daniel PT . (2002). Oncogene, 21, 3149–3161.
Klöpfer A, Hasenjäger A, Belka C, Schulze-Osthoff K, Dörken B and Daniel PT . (2004). Oncogene, 23, 9408–9418.
Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ and Schlesinger PH . (2000). Cell Death Differ., 7, 1166–1173.
LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D and Ashkenazi A . (2002). Nat. Med., 8, 274–281.
Lucking-Famira KM, Daniel PT, Moller P, Krammer PH and Debatin KM . (1994). Leukemia, 8, 1825–1833.
Luo X, Budihardjo I, Zou H, Slaughter C and Wang X . (1998). Cell, 94, 481–490.
Marini P, Jendrossek V, Durand E, Gruber C, Budach W and Belka C . (2003). Radiother. Oncol., 68, 189–198.
Martinou JC and Green DR . (2001). Nat. Rev. Mol. Cell Biol., 2, 63–67.
Mrozek A, Petrowsky H, Sturm I, Krauss J, Hermann S, Hauptmann S, Lorenz M and Daniel P . (2002). Cell Death Differ., 10, 461–467.
Newton K and Strasser A . (2000). J. Exp. Med., 191, 195–200.
Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B and Daniel PT . (2000). Leukemia, 14, 1606–1613.
Prokop A, Wrasidlo W, Lode H, Herold R, Lang F, Henze G, Dörken B, Wieder T and Daniel PT . (2003). Oncogene, 22, 9107–9120.
Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B and Daniel PT . (2002). Oncogene, 21, 227–238.
Raisova M, Bektas M, Wieder T, Daniel P, Eberle J, Orfanos CE and Geilen CC . (2000). FEBS Lett., 473, 27–32.
Raisova M, Hossini A, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE and Geilen CC . (2001). J. Invest. Dermatol., 177, 333–340.
Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S and Belka C . (2005). Oncogene, 24, 130–140.
Schelwies K, Sturm I, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B and Daniel PT . (2002). Int. J. Cancer, 99, 589–596.
Schmelz K, Wieder T, Tamm I, Müller A, Essmann F, Geilen CC, Schulze-Osthoff K, Dörken B and Daniel PT . (2004). Oncogene, 23, 6743–6759.
Slee EA, Keogh SA and Martin SJ . (2000). Cell Death Differ., 7, 556–565.
Sturm I, Bosanquet A, Hermann S, Güner D, Dörken B and Daniel P . (2002). Cell Death Differ., 10, 477–484.
Sturm I, Kohne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B and Daniel PT . (1999). J. Clin. Oncol., 17, 1364–1374.
Sturm I, Papadopoulos S, Hillebrand T, Benter T, Lück H-J, Wolff G, Dörken B and Daniel PT . (2000). Int. J. Cancer, 87, 517–521.
Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B and Daniel PT . (2001). J. Clin. Oncol., 19, 2272–2281.
van Loo G, Saelens X, van Gurp M, MacFarlane M, Martin SJ and Vandenabeele P . (2002). Cell Death Differ., 9, 1031–1042.
von Haefen C, Gillissen B, Hemmati PG, Wendt J, Güner D, Mrozek A, Belka C, Dörken B and Daniel PT . (2004). Oncogene, 23, 8320–8332.
von Haefen C, Wieder T, Essmann F, Schulze-Osthoff K, Dörken B and Daniel PT . (2003). Oncogene, 22, 2236–2247.
von Haefen C, Wieder T, Gillissen B, Stärck L, Graupner V, Dörken B and Daniel PT . (2002). Oncogene, 21, 4009–4019.
Walczak H, Bouchon A, Stahl H and Krammer PH . (2000). Cancer Res., 60, 3051–3057.
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH . (1999). Nat. Med., 5, 157–163.
Waldman T, Lengauer C, Kinzler KW and Vogelstein B . (1996). Nature, 381, 713–716.
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ . (2001). Science, 292, 727–730.
Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E and Bhalla K . (2000). Blood, 96, 3900–3906.
Wesselborg S, Engels IH, Rossmann E, Los M and Schulze-Osthoff K . (1999). Blood, 93, 3053–3063.
Wieder T, Essmann F, Prokop A, Schmelz K, Schulze-Osthoff K, Beyaert R, Dörken B and Daniel PT . (2001). Blood, 97, 1378–1387.
Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X and Shi Y . (2000). Nature, 408, 1008–1012.
Yu J, Wang Z, Kinzler KW, Vogelstein B and Zhang L . (2003). Proc. Natl. Acad. Sci. USA, 100, 1931–1936.
Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B . (2000). Science, 290, 989–992.
Acknowledgements
Bax wild-type and Bax k.o. HCT116 cells were kindly provided by Dr Bert Vogelstein, Johns Hopkins University, Baltimore, USA. We thank Dr Klaus Schulze-Osthoff for supplying us with antibodies against caspase-8. This work was supported by the Deutsche Krebshilfe e.V., the Deutsche Forschungsgemeinschaft, and the Deutsche José Carreras Leukämiestiftung e.V.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wendt, J., von Haefen, C., Hemmati, P. et al. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 24, 4052–4064 (2005). https://doi.org/10.1038/sj.onc.1208580
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208580
Keywords
This article is cited by
-
Bak instead of Bax plays a key role in metformin-induced apoptosis s in HCT116 cells
Cell Death Discovery (2021)
-
Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells
Scientific Reports (2016)
-
Gibberellin derivative GA-13315 sensitizes multidrug-resistant cancer cells by antagonizing ABCB1 while agonizes ABCC1
Cancer Chemotherapy and Pharmacology (2016)
-
Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration
Breast Cancer Research and Treatment (2012)
-
Efficacy of a Triple Treatment with Irradiation, Agonistic TRAIL Receptor Antibodies and EGFR Blockade
Strahlentherapie und Onkologie (2009)